WCLC 2022 | CeLEBrATE: carboplatin, etoposide, bevacizumab and atezolizumab in extensive-stage SCLC
Giuseppe Lamberti, MD, University Hospital of Bologna, Bologna, Italy, provides an overview of the multicenter Phase II CeLEBrATE trial (NCT04730999) investigating carboplatin, etoposide, bevacizumab and atezolizumab in patients with extensive-stage small cell lung cancer (SCLC). The primary endpoint is 1-year over-all survival (OS). The results will be announced in the second half of 2023. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
Transcript (edited for clarity)
CeLEBrATE trial is an ongoing phase two single-arm multicenter trial that we are leading in Italy in patients with extensive stage small cell lung cancer in which patients are receiving carboplatin and etoposide chemotherapy with atezolizumab; that is a PD-L1 inhibitor, so that is a type of immune therapy and bevacizumab; that is a monoclonal antibody against VEGF that is known for its antiangiogenic effects...
CeLEBrATE trial is an ongoing phase two single-arm multicenter trial that we are leading in Italy in patients with extensive stage small cell lung cancer in which patients are receiving carboplatin and etoposide chemotherapy with atezolizumab; that is a PD-L1 inhibitor, so that is a type of immune therapy and bevacizumab; that is a monoclonal antibody against VEGF that is known for its antiangiogenic effects. But VEGF has pleiotropic effects that include also immunosuppressive ones. So the rationale behind the study was that hampering VEGF effects, also immune system, we can enhance the immunotherapy effects in these patients.
Read more...
